Maraviroc, a CCR5 antagonist, could reverse hepatic steatosis, and reduce hepatic triglyceride content in obesity-induced NAFLD mouse models under a high-fat diet (HFD) [13,14]. This evidence concerns the gene CCR5 and obesity due to melanocortin 4 receptor deficiency.